We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Bacterial Contamination Prompts Recall of Concentrate Used in Dialysis

Bacterial Contamination Prompts Recall of Concentrate Used in Dialysis

May 30, 2014

Massachusetts-based Fresenius Medical Care North America has issued two voluntary recalls of a concentrate used in dialysis machines over fears of bacterial contamination, the FDA said.

Fifty-six lots of Fresenius’s NaturaLyte Liquid Bicarbonate Concentrate, 6.4 liters, were pulled during the past two months because the product may develop higher bacteria levels than is allowed by the company’s internal specification, according to the recall notice.

Fresenius’ first customer notification of the Class I recall went out April 10 for 49 lots of the concentrate and the second was sent out May 1 warning of an additional nine lots.

Fresenius said the concentrate was manufactured at its facility in Montreal, Canada, and was distributed between August 2013 and April 7 of this year.

“Laboratory testing has identified the bacteria as Halomonas (species 1, 2, 3), a Gram Negative bacteria, typically found in water with high salinity,” the company said, noting that dialysate contamination has been linked with bacteremia and systemic infection.

Infection is unlikely, however, because of filters used in delivering dialysis create an effective bacteria and endotoxin barrier,” the FDA said.

The FDA announcement made no mention of any reports of people being sickened. In its second letter to customers, Fresenius said that “no pyrogenic reactions, bacterial infections or related adverse events have been reported.”

Fresenius is a division of Fresenius Medical Care, which supplies more than 2,150 dialysis centers throughout North America with dialysis equipment and products as well as renal pharmaceuticals.

Fresenius did not respond to requests for comment by press time.

Don’t let contamination cause a recall; purchase Manufacturing Sterile Products to Meet EU and FDA Guidelines today!

Medical Devices Postmarket Safety Commercial Operations

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

  • 10Feb

    FDA Under the Biden Administration: What’s to Come and What It Will Mean

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Supreme Court Rejects Merck’s Appeal for $2.5 Billion Patent Verdict Reinstatement

  • FDA clears text

    FDA Clears SCC’s Transfusion-Management Software

  • CE mark

    MiRXES Earns CE Mark for COVID-19/Flu Test

  • KitePharma_Logo

    Kite Pharma’s Tecartus Gains UK Recommendation for Lymphoma

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing